-
In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
-
The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif
-
The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
-
Women who took COPAXONE® (glatiramer acetate injection) during part of their pregnancies demonstrated no more risk than the general population of pregnancy outcomes, according to an abstract presented this week at the American Academy of Neurology (AAN).
-
Generic drug maker Teva Pharmaceutical Industries Ltd. said Monday new data from a study of its multiple sclerosis drug reinforce previous information that the treatment reduces relapses of symptoms and may slow tissue damage associated with the disease.
-
Treatment of relapsing-remitting multiple sclerosis (MS) with glatiramer-acetate (glatiramer, Copaxone) is safe and effective, and it has a positive impact on average relapse rate and disease progression scores.
-
A new study showed that very active patients who received COPAXONE(R) (glatiramer acetate injection) therapy alone following short-term induction treatment with mitoxantrone experienced an 89 percent greater reduction (Pless than0.0001) compared to those
-
Teva Pharmaceutical Industries Ltd. announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study which compared a new higher dose of 40 mg/day dose of glatiramer acetate (GA) to the currently approve
-
To review the latest information on the side effects associated with the available disease-modifying therapies (DMTs) used to treat relapsing-remitting multiple sclerosis (RRMS) and to offer strategies for their management
-
Researchers have found a new explanation for the effects of Copaxone® (glatiramer acetate, Teva Pharmaceuticals), a treatment approved for relapsing-remitting multiple sclerosis
-
Here we describe many of the new medications and treatment approaches that are already being tested in clinical studies
-
A three-year controlled study is being launched at 10 centers across the United Kingdom to further investigate the potential of the drug combination. The results of the initial trial, led by Dr. Mike Boggild at the Walton Centre in Liverpool, will be publ
-
The United Kingdom early Mitoxantrone Copaxone trial is a controlled study which will compare combination therapy with mitoxantrone and Glatiramer Acetate (Copaxone) against high dose interferon beta treatment (Rebif 44).
-
Doctors at Walton began treating patients with a combination of a chemotherapy drug normally used to treat cancer called mitoxantrone, with an MS anti-relapse drug Copaxone, in 2001.
-
The treatment regime, consisting of a limited course of mitoxantrone (an immunosuppressant normally used to treat cancer) followed by long-term glatiramer acetate (Copaxone - one of two classes of disease modifying drugs for use in relapsing-remitting mul
